Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium

European Journal of Pediatrics

Volumn 174, Issue 7, 2015, Pages 925-932

  Leuridan, E ^a   Maertens, K ^a   Wautier, M ^b   Hutse, V ^b   Theeten, H ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

Measles; Mumps; Rubella; Schedule; Susceptibility; Vaccination

Indexed keywords

MATERNAL ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ACUTE LEUKEMIA; ANTIBODY TITER; ARTICLE; BELGIUM; CHILD; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASLES; MUMPS; PRESCHOOL CHILD; PRIORITY JOURNAL; RUBELLA; SEROPREVALENCE; BLOOD; COHORT ANALYSIS; DISEASE PREDISPOSITION; EPIDEMIOLOGY; IMMUNIZATION; IMMUNOLOGY; MULTIVARIATE ANALYSIS; SECONDARY IMMUNIZATION;

ANTIBODIES, VIRAL; BELGIUM; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE SUSCEPTIBILITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; MALE; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; MULTIVARIATE ANALYSIS; MUMPS; RUBELLA; SEROEPIDEMIOLOGIC STUDIES;

EID: 84935016798     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-014-2481-5     Document Type: Article

References (40)

1. Abrams S, Beutels P, Hens N (2014) Assessing mumps outbreak risk in highly vaccinated populations using spatial seroprevalence data. Am J Epidemiol 179(8):1006–1017. doi:10.1093/aje/kwu014
2. Allwinn R, Zeidler B, Steinhagen K, Rohwader E, Wicker S, Rabenau HF, Doerr HW (2011) Assessment of mumps virus-specific antibodies by different serological assays: which test correlates best with mumps immunity? Eur J Clin Microbiol Infect Dis 30(10):1223–1228. doi:10.1007/s10096-011-1216-z
3. American Academy of Pediatrics. Committee on Infectious Diseases (1998) Age for routine administration of the second dose of measles-mumps-rubella vaccine. Pediatrics 101(1 Pt 1):129–133
4. Bernaola Iturbe E, Gimenez Sanchez F, Baca Cots M, de Juan Martin F, Diez Domingo J, Garces Sanchez M, Gomez-Campdera A, Martinon-Torres F, Picazo JJ, Pineda Solas V (2007) Vaccination schedule of the Spanish Association of Pediatrics: recommendations 2007. An Pediatr (Barc) 66(1):62–69
5. Braeckman T, Lernout T, Top G, Paeps A, Roelants M, Hoppenbrouwers K, Van Damme P, Theeten H (2014) Assessing vaccination coverage in infants, survey studies versus the Flemish immunisation register: achieving the best of both worlds. Vaccine 32(3):345–349. doi:10.1016/j.vaccine.2013.11.041
6. Braeye T, Linina I, De Roy R, Hutse V, Wauters M, Cox P, Mak R (2014) Mumps increase in Flanders, Belgium, 2012–2013: results from temporary mandatory notification and a cohort study among university students. Vaccine 32(35):4393–4398. doi:10.1016/j.vaccine.2014.06.069
7. Cook IF (2008) Sexual dimorphism of humoral immunity with human vaccines. Vaccine 26(29–30):3551–3555. doi:10.1016/j.vaccine.2008.04.054
8. Davidkin I, Kontio M, Paunio M, Peltola H (2010) MMR vaccination and disease elimination: the Finnish experience. Expert Rev Vaccines 9(9):1045–1053. doi:10.1586/erv.10.99
9. ECDC (2013) Annual epidemiological report 2013. http://ecdc.europa.eu/en/publications/Publications/annual-epidemiological-report-2013.pdf.Accessed 25/11/2014
10. Edmonson MB, Davis JP, Hopfensperger DJ, Berg JL, Payton LA (1996) Measles vaccination during the respiratory virus season and risk of vaccine failure. Pediatrics 98(5):905–910
11. Eriksen J, Davidkin I, Kafatos G, Andrews N, Barbara C, Cohen D, Duks A, Griskevicius A, Johansen K, Bartha K, Kriz B, Mitis G, Mossong J, Nardone A, O'Flanagan D, DE Ory F, Pistol A, Theeten H, Prosenc K, Slacikova M, Pebody R (2013) Seroepidemiology of mumps in Europe (1996-2008): why do outbreaks occur in highly vaccinated populations?. Epidemiol Infect 141(3):651–666. doi:10.1017/S0950268812001136
12. Euvac.net. http://ecdc.europa.eu/EN/ACTIVITIES/SURVEILLANCE/EUVAC/Pages/index.aspx. Accessed 25/11/2014
13. Filipse W (2014) Het honderddagenfeest en de bof in Vlaanderen in 2013. Vlaams infectieziektebulletin 2014/2
14. Gans HA, Yasukawa LL, Sung P, Sullivan B, DeHovitz R, Audet S, Beeler J, Arvin AM (2013) Measles humoral and cell-mediated immunity in children aged 5–10 years after primary measles immunization administered at 6 or 9 months of age. J Infect Dis 207(4):574–582. doi:10.1093/infdis/jis719
15. Vlaams Agentschap Zorg & Gezondheid (2012) Meldingen infectieziekten 2006–2014. http://www.zorg-en-gezondheid.be/Cijfers/Ziekten/Infectieziekten-en-vaccinatie/Meldingen-infectieziekten-2006-2014/. Accessed 25/11/2014
16. Gidding HF (2005) The impact of Australia’s measles control programme over the past decade. Epidemiol Infect 133(1):99–105
17. Gil Miguel A, Astasio Arbiza P, Ortega Molina P, Dominguez Rojas V, Gonzalez Lopez A (1999) Seroprevalence of antibodies against measles, rubella, mumps and varicella among school children in Madrid. An Esp Pediatr 50(5):459–462
18. Hahne S, te Wierik MJ, Mollema L, van Velzen E, de Coster E, Swaan C, de Melker H, van Binnendijk R (2008) Measles outbreak, the Netherlands. Emerg Infect Dis 16(3):567–569
19. Comité voor de Eliminatie van Mazelen en Rubella in België (2013) Actieplan 2012–2015 Bijwerking tot mei 2013. https://www.wiv-isp.be/Epidemio/epinl/plabnl/D_2013_2505_27.pdf. Accessed 25/11/2014
20. Johnson CE, Kumar ML, Whitwell JK, Staehle BO, Rome LP, Dinakar C, Hurni W, Nalin DR (1996) Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Pediatr Infect Dis J 15(8):687–692
21. Koen De Schrijver VB, Daniel Van den Branden (2012) Bofopstoot in de provincie Antwerpen in 2011. Vlaams Infectieziekten Bulletin 80/2012/2
22. LeBaron CW, Beeler J, Sullivan BJ, Forghani B, Bi D, Beck C, Audet S, Gargiullo P (2007) Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch Pediatr Adolesc Med 161(3):294–301
23. Lernout T, Kissling E, Hutse V, De Schrijver K, Top G (2009) An outbreak of measles in orthodox Jewish communities in Antwerp, Belgium, 2007–2008: different reasons for accumulation of susceptibles. Euro Surveill 14(2)
24. Lernout T, Theeten H, Hens N, Braeckman T, Roelants M, Hoppenbrouwers K, Van Damme P (2014) Timeliness of infant vaccination and factors related with delay in Flanders, Belgium. Vaccine 32(2):284–289. doi:10.1016/j.vaccine.2013.10.084
25. Leuridan E, Goeyvaerts N, Hens N, Hutse V, Van Damme P (2012) Maternal mumps antibodies in a cohort of children up to the age of 1 year. Eur J Pediatr. doi:10.1007/s00431-012-1691-y
26. Leuridan E, Hens N, Hutse V, Aerts M, Van Damme P (2011) Kinetics of maternal antibodies against rubella and varicella in infants. Vaccine 29(11):2222–2226. doi:10.1016/j.vaccine.2010.06.004
27. Leuridan E, Hens N, Hutse V, Ieven M, Aerts M, Van Damme P (2010) Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. Br Med J 340:c1626
28. Markowitz LE, Albrecht P, Orenstein WA, Lett SM, Pugliese TJ, Farrell D (1992) Persistence of measles antibody after revaccination. J Infect Dis 166(1):205–208
29. Mathias RG, Meekison WG, Arcand TA, Schechter MT (1989) The role of secondary vaccine failures in measles outbreaks. Am J Public Health 79(4):475–478
30. Measles vaccines: WHO position paper (2009). Releve epidemiologique hebdomadaire / Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations 84 (35):349–360
31. Mitchell LA (1999) Sex differences in antibody- and cell-mediated immune response to rubella re-immunisation 5. J Med Microbiol 48(12):1075–1080
32. Muscat M (2011) Who gets measles in Europe? J Infect Dis 204(Suppl 1):S353–S365. doi:10.1093/infdis/jir067
33. Orlikova H, Rogalska J, Kazanowska-Zielinska E, Jankowski T, Slodzinski J, Kess B, Stefanoff P (2010) Spotlight on measles 2010: a measles outbreak in a Roma population in Pulawy, eastern Poland, June to August 2009. Euro Surveill 15(17)
34. Pebody RG, Gay NJ, Hesketh LM, Vyse A, Morgan-Capner P, Brown DW, Litton P, Miller E (2002) Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance. Vaccine 20(7–8):1134–1140
35. Rogers KD, Ramirez G, Cortez M, Michaels R, Savin M, Montgomery R, Welty T, Taylor F, Hingson RA (1971) Clinical response to immunization with Cendehill strain rubella vaccine. Pediatrics 47(1):7–15
36. Schmid D, Holzmann H, Schwarz K, Kasper S, Kuo HW, Aberle SW, Redlberger-Fritz M, Hautmann W, Santibanez S, Mankertz A, Konig C, Magnet E, Reichart S, Meusburger S, Luckner-Hornischer A, De Martin A, Bechter E, Stirling J, Allerberger F (2010) Measles outbreak linked to a minority group in Austria, 2008. Epidemiol Infect 138(3):415–425. doi:10.1017/S0950268809990604
37. Theeten H, Roelants M, Lernout T, Braeckman T, Hens N, Hoppenbrouwers K, Van Damme P (2013) Studie van de vaccinatiegraad bij jonge kinderen en adolescenten in Vlaanderen in 2012. http://www.zorg-en-gezondheid.be/vaccinatiegraad/. Accessed 25/11/2014
38. Tischer A, Andrews N, Kafatos G, Nardone A, Berbers G, Davidkin I, Aboudy Y, Backhouse J, Barbara C, Bartha K, Bruckova B, Duks A, Griskevicius A, Hesketh L, Johansen K, Jones L, Kuersteiner O, Lupulescu E, Mihneva Z, Mrazova M, De Ory F, Prosenc K, Schneider F, Tsakris A, Smelhausova M, Vranckx R, Zarvou M, Miller E (2007) Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia. Epidemiol Infect 135(5):787–797. doi:10.1017/s0950268807008266
39. Vandermeulen C, Mathieu R, Geert LR, Pierre VD, Karel H (2007) Long-term persistence of antibodies after one or two doses of MMR-vaccine. Vaccine 25(37–38):6672–6676
40. Vandermeulen C, Roelants M, Vermoere M, Roseeuw K, Goubau P, Hoppenbrouwers K (2004) Outbreak of mumps in a vaccinated child population: a question of vaccine failure? Vaccine 22(21–22):2713–2716